Navigation Links
PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
Date:6/16/2008

30 a.m.)

-- Data-driven Patient Recruitment: Tools for Early Planning and

Predictive Management: Approaches to Data-driven Site Selection and LPI

Planning -- Session Chair and Speaker: Joshua Schultz, MS, Vice

President, Clinical Research Services, PAREXEL (2:00 p.m. -- 3:30 p.m.)

-- Innovative Medicines and the EMEA: Strategizing for Success in the EU

-- Session Chair and Speaker: Cecil Nick, MS, Vice President,

Biotechnology, PAREXEL Consulting (2:00 p.m. -- 3:30 p.m.)

-- Evolving Natural Health Products Market Size and Its Development.

Cosmeceuticals: Marketing Topical Products without Making Licensable

Medicinal Claims in Europe -- Peter Lassoff, PharmD, Vice President,

PAREXEL Consulting (4:00 p.m. -- 5:30 p.m.)

Wednesday, June 25

-- Imaging Biomarker Data Management: Qualification and Validation of

Imaging Biomarkers -- George Q. Mills, MD, Vice President, Medical

Imaging Consulting, Perceptive Informatics (8:30 a.m. -- 10:00 a.m.)

-- Biosimilars/Follow-on Biologics: Unique Aspects of the Development of

Follow-On Biologics Products -- Session Chair and Speaker: Bruce

Babbitt, PhD, Principal Consultant, PAREXEL Consulting

(8:30 a.m. -- 10:00 a.m.)

-- The Expanding Use of Genomics Studies Methods, Regulatory

Considerations and the Impact on Evidence-Based Medicine -- Session

Chair: Nayan Nanavati, MS, MT, Vice President Peri Approval, Americas,

PAREXEL; Speaker: Ramita Tandon, Director, Project Management, Clinical

Research Services, PAREXEL (8:30 a.m. -- 10:00 a.m.)

-- Opportunities and Challenges of Globalizing Clinical Research: Adding

Value to Early-stage Biotechnology Product Development -- Matthias

Grossmann, MD, PhD, Vice President and Principal Consultant, Clinical

Pharmacology, PAREXEL (10:30 a.m.-- 12:00 p.m.)

--
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PAREXEL Reaches Agreement To Acquire ClinPhone
2. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
3. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
4. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
5. PAREXEL Reports Third Quarter Fiscal Year 2008 Financial Results
6. PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference
7. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
8. PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
9. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
10. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
11. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 26, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... study protocol for the company,s Phase IIb trial of ... and Drug Administration (FDA). The submission was made under ... The Phase IIb study of ORMD-0801 for type ...
(Date:5/26/2015)... Just the characterization of being a new ... does not guarantee immediate acceptance. In particular, a ... prior failures is often met with significant skepticism. ... irony that is often an unappreciated aspect of scientific ... Asymmetrex has found that building acceptance of its ...
(Date:5/22/2015)... -- Actavis plc (NYSE: ACT ) today confirmed that ... the Second Circuit has issued a ruling upholding a ... continue distribution of NAMENDA ® (memantine HCl) immediate-release ... "While we are disappointed by the Court,s ... our strong efforts to convey the significant benefits of ...
(Date:5/21/2015)... TORONTO , May 21, 2015 /PRNewswire/ - SQI ... SQIDF),a life sciences company that develops and commercializes proprietary ... its financial and operational results for the second fiscal ... the quarter the Company continued to advance business with ... Andrew Morris , President and CEO of SQI. ...
Breaking Biology Technology:Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8
... Feb. 11 AGA Medical Corporation ("AGA"),announced today it ... II ("ADO II"). AGA also announced the immediate availability,and ... expands the AGA family of,occlusion devices designed to occlude ... congenital heart defect that occurs when a blood vessel,called ...
... VaxGen, Inc. (Pink Sheets:,VXGN), WHAT: Jim Panek, CEO of VaxGen, and George ... update on Raven,s oncology pipeline, discuss the ... plans and prospects for the new Company., WHEN: 2:45 p.m. EST, Wednesday, February ... go to VaxGen@BIOCEO, ...
... theoretical question, "Can one hear the shape of a drum?" ... unique sound spectrum, then it should be possible to identify ... spectrum, thus "hearing" the drum,s shape (a procedure analogous to ... star by studying its light spectrum). , But what if ...
Cached Biology Technology:AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II 2VaxGen to Present at the 10th Annual BIO CEO and Investor Conference 2VaxGen to Present at the 10th Annual BIO CEO and Investor Conference 3Stanford researchers hear the sound of quantum drums 2Stanford researchers hear the sound of quantum drums 3
(Date:5/21/2015)... May 21, 2015 The Sync Project™ ... music for health, today announced a collaborative partnership with ... partnership will center on collaboration on original research, joint ... step in the collaboration, The Sync Project and BerkleeICE ... as Medicine" in the 2015-2016 academic year.  ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
(Date:5/19/2015)... NEW YORK , May 19, 2015  Technology ... resources both internally and in the cloud. Passwords and ... the use of OTP and standards-based specifications such as ... that the outmoded use of passwords presents for BYOD, ... needs a unified biometric identity protocol. ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3
... Oct. 3, 2011 Complete Genomics Inc. (NASDAQ: GNOM), ... Scripps Health system today announced a major collaboration that ... research initiative aimed at unlocking the genetic secrets of ... sequence, at its own cost, the whole human genomes ...
... the Galpagos mockingbirds had a great influence on Charles ... of the four mockingbird species are among the rarest ... Central,s open access journal BMC Evolutionary Biology untangles the ... their parasites to help ensure the birds survival. ...
... Most of the time, the immune system is the body,s ... lead to infection and disease. But in autoimmune diseases, ... body and attacking normal cells. A major discovery by ... of a previously unknown molecular interaction that is essential for ...
Cached Biology News:Scripps and Complete Genomics to collaborate on genetic research study on healthy aging 2Scripps and Complete Genomics to collaborate on genetic research study on healthy aging 3A hitchhiker's guide to the Galápagos: co-evolution of Galápagos mockingbirds and their parasites 2La Jolla Institute discovers previously unknown cell interaction key in immune system attacks 2La Jolla Institute discovers previously unknown cell interaction key in immune system attacks 3
Normal human AB serum, pooled...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
XBP1 Antibody...
Recombinant Mouse MMP-9, CF...
Biology Products: